Centenary Institute scientists have successfully created a more realistic model of primary liver cancer; placing medical researchers in a much better position to develop more effective treatments for the third-most common cause of cancer death worldwide.
“Our novel model has progressed two key areas: fast-tracking the time it takes to conduct modelling, while more closely replicating liver cancer drivers that occur in humans,” says PhD student James Henderson, lead author on the study.
“This places researchers in a much better position to develop effective therapies in future to treat liver cancer in the early stages; reducing the burden on Australia’s health-care system and improving patient outcomes.”
Research from the Centenary Institute has found that the human enzyme DPP4 does not enable COVID-19 infection in our bodies.
Professor John Rasko AO has led a world-first clinical trial into engineered stem cell treatment use, treating 15 patients with steroid resistant acute graft-versus-host disease.
Centenary Institute research has discovered that the lack of an enzyme in the liver called sphingosine kinase 2 results in pronounced insulin resistance and glucose intolerance, both symptoms of early stage type 2 diabetes.